AUSTRALIAN BREAST CANCER PATIENTS ENROLLED IN THE LAPATINIB EXPANDED ACCESS PROGRAM (LEAP)

被引：0
|
作者：
Lynch, J. [1 ,2 ]
Boyle, F. [3 ]
Wilkin, N. [4 ]
Hague, C. [5 ]
机构：
[1] St George Hosp, Canc Serv, Kogarah, NSW, Australia
[2] Sutherland Hosp, Canc Serv, Kogarah, NSW, Australia
[3] Mater Hosp, Sydney, NSW, Australia
[4] Westmead Hosp, Westmead, NSW 2145, Australia
[5] Sutherland Hosp, Caringbah, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [41] Quality of life of patients with advanced breast cancer treated with lapatinib and capecitabine
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2012, 8 (05): : 204 - 208
  • [42] Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients
    Keyvan Rezai
    S. Urien
    N. Isambert
    H. Roche
    V. Dieras
    J. Berille
    J. Bonneterre
    E. Brain
    F. Lokiec
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1529 - 1536
  • [43] Clinical Outcomes of Brain Metastasis by Lapatinib (L) and Capecitabine (C) in an Open-Label Expanded Access Study among Korean Patients with HER2 Positive Metastatic Breast Cancer
    Ro, J.
    Park, S.
    Kim, S-B
    Kim, T-Y
    Im, Y-H
    Rha, S. Y.
    Chung, J. S.
    Moon, H.
    Santillana, S.
    CANCER RESEARCH, 2010, 70
  • [44] MRI screening for breast cancer in women at high risk; isthe Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer?
    Schenberg, Tess
    Mitchell, Gillian
    Taylor, Donna
    Saunders, Christobel
    JOURNAL OF MEDICAL RADIATION SCIENCES, 2015, 62 (03): : 212 - 225
  • [45] Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer
    Ohgami, M.
    Bando, H.
    Ishiguro, H.
    Tsuda, M.
    Toriguchi, N.
    Aogi, K.
    Toi, M.
    Masuda, N.
    Mitsuhashi, S.
    Kurosawa, A.
    Homma, M.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2888 - 2889
  • [46] Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access "BALLET" study
    Generali, D.
    Bordonaro, R.
    Febbraro, A.
    Madoffa, A.
    Romito, S.
    Michelotti, A.
    Savastano, C.
    Mariani, G.
    Tondini, C.
    Piovano, P.
    Iona, M. T.
    Bighin, C.
    Roviello, G.
    Ascione, G.
    Goffredo, F.
    Sartori, D.
    Frassoldati, A.
    Simoncini, E.
    CANCER RESEARCH, 2017, 77
  • [47] A comparative analysis of breast cancer stage between women enrolled in the National Breast and Cervical Cancer Early Detection Program and women not participating in the program
    Wu, Manxia
    Austin, Harland
    Eheman, Christie R.
    Myles, Zachary
    Miller, Jacqueline
    Royalty, Janet
    Ryerson, A. Blythe
    CANCER CAUSES & CONTROL, 2015, 26 (05) : 751 - 758
  • [48] A comparative analysis of breast cancer stage between women enrolled in the National Breast and Cervical Cancer Early Detection Program and women not participating in the program
    Manxia Wu
    Harland Austin
    Christie R. Eheman
    Zachary Myles
    Jacqueline Miller
    Janet Royalty
    A. Blythe Ryerson
    Cancer Causes & Control, 2015, 26 : 751 - 758
  • [49] Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.
    Philip, Philip Agop
    Smaglo, Brandon George
    El-Rayes, Bassel F.
    Lesuisse, Christian
    Makris, Lukas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials
    Lynce, Filipa
    Blackburn, Matthew J.
    Cai, Ling
    Wang, Heping
    Rubinstein, Larry
    Harris, Pamela
    Isaacs, Claudine
    Pohlmann, Paula R.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 35 - 41
12345